Mesenchymal Neuroblastoma Cells Are Undetected by Current mRNA Marker Panels: The Development of a Specific Neuroblastoma Mesenchymal Minimal Residual Disease Panel

Esther M. van Wezel, MD, PhD1,2; Lieke M.J. van Zogchel, MD1,3; Jalenka van Wijk, MSc1,2; Ilse Timmerman, PhD1,3; Ngoc-Kim Vo1; Lily Zappeij-Kannegieter1; Boris de Carolis, MD4; Thorsten Simon, MD4; Max M. van Noesel, MD, PhD3; Jan J. Molenaar, MD, PhD3; Tim van Groningen, MSc2; Rogier Versteeg, PhD2; Huib N. Caron, MD, PhD2; C. Ellen van der Schoot, MD, PhD1; Jan Koster, PhD2; Johan van Nes, PhD2; and Godelieve A.M. Tytgat, MD, PhD2,3

PURPOSE Patients with neuroblastoma in molecular remission remain at considerable risk for disease recurrence. Studies have found that neuroblastoma tissue contains adrenergic (ADRN) and mesenchymal (MES) cells; the latter express low levels of commonly used markers for minimal residual disease (MRD). We identified MES-specific MRD markers and studied the dynamics of these markers during treatment.

PATIENTS AND METHODS Microarray data were used to identify genes differentially expressed between ADRN and MES cell lines. Candidate genes were then studied using real-time quantitative polymerase chain reaction in cell lines and control bone marrow and peripheral blood samples. After selecting a panel of markers, serial bone marrow, peripheral blood, and peripheral blood stem cell samples were obtained from patients with high-risk neuroblastoma and tested for marker expression; survival analyses were also performed.

RESULTS PRRX1, POSTN, and FMO3 mRNAs were used as a panel for specifically detecting MES mRNA in patient samples. MES mRNA was detected only rarely in peripheral blood; moreover, the presence of MES mRNA in peripheral blood stem cell samples was associated with low event-free survival and overall survival. Of note, during treatment, serial bone marrow samples obtained from 29 patients revealed a difference in dynamics between MES mRNA markers and ADRN mRNA markers. Furthermore, MES mRNA was detected in a higher percentage of patients with recurrent disease than in those who remained disease free (53% vs 32%, respectively; P = .03).

CONCLUSION We propose that the markers POSTN and PRRX1, in combination with FMO3, be used for real-time quantitative polymerase chain reaction–based detection of MES neuroblastoma mRNA in patient samples because these markers have a unique pattern during treatment and are more prevalent in patients with poor outcome. Together with existing markers of MRD, these new markers should be investigated further in large prospective studies.

INTRODUCTION

Despite intensive multimodality therapy, patients with high-risk neuroblastoma often experience a relapse.1-7 Because the bone marrow (BM) is a common site of recurrence, residual neuroblastoma cells are believed to be the major cause of relapse.9

Real-time quantitative polymerase chain reaction (RT-qPCR) provides a highly sensitive means of detecting minimal residual disease (MRD) in peripheral blood (PB), BM, and peripheral blood stem cells (PBSCs).9,10 Although the detection of MRD markers in high-risk neuroblastoma has been correlated with poor outcome,11-13 many patients who become negative for these markers still experience relapse.11 Epithelial-to-mesenchymal transition (EMT)—the process by which epithelial cells transform to a mesenchymal (MES) phenotype—is associated with tumor progression, metastasis, and therapy resistance in several cancer types.20-23 For example, in patients with breast cancer, the presence of circulating MES tumor cells is associated with disease progression, metastasis, and therapy resistance in several cancer types.20-23 For example, in patients with breast cancer, the presence of circulating MES tumor cells is associated with disease progression, metastasis, and therapy resistance in several cancer types.20-23 Of note, these cells do not express the commonly used neuroblastoma markers PHOX2B or DBH.24

MRD marker selection often is primarily based on expression levels in adrenergic (ADRN) cell lines and primary neuroblastoma tumors.10,15,28,29 We
identified neuroblastoma-specific MES mRNA markers for detecting MES neuroblastoma cells and then examined the dynamics of these MES markers in samples obtained from patients with high-risk neuroblastoma.

**PATIENTS AND METHODS**

**Cell Lines and Cell Culture**

SH-EP2, SH-SY5Y, IMR-32, 691-MES, and 691-ADRN cells were cultured as previously described.30,31

**Microarray Analysis**

Gene expression analysis to detect MES-specific and mesenchymal stromal cell (MSC)–discriminating candidate markers can be found in the Appendix.

**Patients and Samples**

We analyzed samples (stored remains) obtained from 38 patients with high-risk neuroblastoma treated in accordance with the German NB2004 or Dutch NBL2009 trial32,33 (Data Supplement). Written informed consent was provided by the patients’ parents or guardians. The study was approved by the medical ethics committees (Academic Medical Center, Amsterdam, the Netherlands; MEC07/219#08.17.0836) and the University of Cologne. Clinical samples were collected in EDTA tubes, processed within 24 hours, transferred to PAXgene Blood RNA Tubes (QIAGEN, Venlo, the Netherlands), and stored at −20 °C. DNA was isolated from mononuclear cells stored in 10% dimethylsulfoxide at −180 °C, and hypermethylated RASSF1A RT-qPCR was performed as described previously.34

**RNA Extraction and RT-qPCR**

RNA was isolated from clinical and control samples using the PAXgene Blood RNA Kit (QIAGEN). RNA was isolated from cell lines using TRIzol (Invitrogen, Carlsbad, CA) according to the manufacturer’s instructions. Methods for cDNA synthesis and RT-qPCR can be found in the Appendix. Expression was normalized to GUSB expression using the following equation: normalized threshold cycle (dCt) = (CtGUSB − Ctmarker).

**Data Analysis**

For the newly identified MES markers, a threshold for positivity in control BM, PB, and PBSC samples was determined on the basis of their expression in each sample (see Results). In the PBSC cohort, survival was analyzed using the Kaplan-Meier method, and significant differences between the estimated survival curves were analyzed using the log-rank test. Fisher’s exact test was used to analyze the differences in MES marker positivity between the relapse and survivor groups. All statistical analyses were performed using SPSS version 23 software (IBM Corporation, Chicago, IL).

**RESULTS**

**Expression of Commonly Used MRD Markers in a Panel of Neuroblastoma Cell Lines**

The expression of commonly used MRD markers (PHOX2B, TH, DDC, DBH, GAP43, CHRNA3, and
GD2S [30,36,37] was measured in two isogenic neuroblastoma cell line pairs (691-MES/691-ADRN and SH-EP2/SH-SY5Y) and in one ADRN cell line (IMR-32). Compared with the corresponding ADRN cell lines, the MES cell lines had significantly lower, albeit variable, expression of six markers; in contrast, GD2S was expressed at high levels in both the MES and the ADRN cell lines (Fig 1).

**Identification of Candidate MES Markers for MRD Testing**

To detect MES cells in the context of MRD, we compared the gene expression data between pairs of isogenic cell lines and then selected the genes that were significantly upregulated in the MES cell lines compared with the corresponding ADRN cell line and expressed at high levels in MES cells (defined as > 400 units). Subsequently, we filtered for genes with a minimal expression level in PB data sets, which resulted in an initial list of 14 candidate genes (Fig 2A). All 14 of these genes were included in the MES gene signature reported recently by van Groningen et al [24] (Fig 2B). Although PRRX1 was not included in this initial list because its expression in 700-MES cells was less than 400, we included this gene in our additional analyses because PRRX1 was reported as an immunohistochemistry marker for MES neuroblastoma.

**Validation of Candidate Markers**

Using RT-qPCR with SYBR Green I dye (Applied Biosystems, Foster City, CA), we examined the expression of all 15 candidate markers in MES cells (691-MES and SH-EP2), ADRN cells (691-ADRN, SH-SY5Y, and IMR-32), and a control PB sample (Data Supplement). As a result of culture problems, 700-ADRN/700-MES was not used for RT-qPCR testing. Our analysis revealed three genes with high expression in MES cells, a significant difference in expression between the MES and ADRN cell lines, and either low or no measurable expression in the control PB sample; these three genes were POSTN, PRRX1, and COL3A1, which encode the proteins periostin, paired related homeobox 1, and collagen type III α1, respectively.

RT-qPCR using TaqMan probes validated expression of these markers, which demonstrated high POSTN, PRRX1, and COL3A1 expression in 691-MES and SH-EP2 and low expression in 691-ADRN, SH-SY5Y, and IMR-32 (Fig 3A). COL3A1 was then excluded because it did not adequately discriminate between ADRN and MES cell lines and was detected in the control PB samples.

Next, to set thresholds for defining positivity, we measured the expression of POSTN and PRRX1 in normal hematologic cells: control BM samples (n = 48), PB samples (n = 104), and PBSCs (n = 29). We measured extremely low expression (or no expression) of both genes in control PBSCs. However, because both POSTN and PRRX1 were expressed at variable levels in the control BM and PB samples (Fig 3B), we examined their expression levels in several subsets of hematologic cells and in MSCs (Fig 3C). We found that both POSTN and PRRX1 were robustly expressed in MSCs and, to a lesser extent, in T cells; in contrast, POSTN was expressed at extremely low levels in B cells. Taken together, these results suggest that the presence of both POSTN and PRRX1 in control BM and PB samples is likely the result of their expression in MSCs.

**Identification of an MSC-Discriminating Marker**

Next, we searched for a marker that can be used to discriminate between MSCs and MES mRNA. Microarray analysis identified 14 candidate genes that were highly expressed in MSCs but poorly expressed both in MES cell lines and in hematologic cells (not containing MSCs; Fig 4A; Data Supplement). The specificity of these markers was then tested using MSCs obtained from healthy individuals (n = 2), neuroblastoma cell lines (n = 5), and control PB samples (n = 2) using SYBR Green I dye (Data Supplement). Our analysis revealed that the FMO3 gene (encoding flavin-containing monoxygenase 3) was the most promising marker for discriminating between MSCs and MES cells. Subsequent testing using an FMO3-specific TaqMan probe confirmed high expression in MSCs (comparable to the expression levels of PRRX1 and POSTN), low expression (or no expression) in all neuroblastoma cell lines (Fig 4B), and no expression in hematologic subsets that lacked MSCs.

**Threshold for Positivity in BM, PB, and PBSCs**

Because MSCs, and to a lesser extent, B cells and T cells, express low levels of POSTN and PRRX1, we established a threshold for positivity for MES mRNA detection in control BM, PB, and PBSC samples. Forty-eight control BM samples were analyzed for PRRX1, POSTN, and FMO3 expression (Data Supplement). In 77% of the control BM samples (37 of 48), FMO3 expression was similar to or
**FIG 2.** Identification of candidate mesenchymal (MES) markers of minimal residual disease (MRD). (A) Flowchart that shows the strategy used to identify putative MES markers. (B) Heat map that shows the expression profiles of the indicated 35 genes with high expression (red) in MES cell lines (right) and low expression (green) in adrenergic (ADRN) cell lines (left); shown underneath are genes that are commonly used for MRD testing in neuroblastoma. Subsequent filtering for minimal gene expression in normal peripheral blood data sets resulted in 14 candidate MES markers for MRD (underlined in red).
higher than POSTN and PRRX1; in contrast, POSTN and PRRX1 expression levels were higher than FMO3 in the remaining 11 control samples (> 1 dCt between FMO3 and POSTN/PRRX1). On the basis of these results, the positivity threshold for POSTN and PRRX1 was set to a dCt value greater than −9 between POSTN/PRRX1 and GUSB and a dCt value greater than 3 between POSTN/PRRX1 and FMO3 (Fig 4C). The threshold for positivity for PB was determined using 104 control PB samples (Data Supplement) and was set to a dCt value greater than −12 for PRRX1 and a dCt value greater than 10 for POSTN, with no measurable expression of FMO3. Because the background expression of both POSTN and PRRX1 was extremely low in control PBSC samples, each PBSC sample was scored as

FIG 3. Real-time quantitative polymerase chain reaction analysis of three putative mesenchymal (MES) markers in cell lines and control samples. (A) The indicated genes were measured in MES cell lines (shown in blue) and adrenergic (ADRN) cell lines (shown in red). Blue squares, 691-MES; blue circles, SH-EP2; red circles, SH-SY5Y; red squares, 691-ADRN; red diamonds, IMR-32. Normalized expression (dCt = CtGUSB − Ctmarker) is shown. (B) Normalized expression (dCt = CtGUSB − Ctmarker) of POSTN and PRRX1 measured in control bone marrow (BM), peripheral blood (PB), and peripheral blood stem cell (PBSC) samples. Pos NQR indicates samples that were positive but not within the quantifiable range. (C) Normalized expression of POSTN (circles) and PRRX1 (triangles) measured in the indicated hematologic cell types in control blood. MSC, mesenchymal stromal cell; NK, natural killer.

FIG 4. Identification of mesenchymal stromal cell (MSC)–specific markers. (A) Flowchart that shows the strategy used to identify MSC markers. (B) Normalized expression (dCt = CtGUSB — Ctmarker) of FMO3, POSTN, PRRX1, and PHOX2B in MSCs and neuroblastoma cell lines. Mesenchymal (MES) and adrenergic (ADRN) neuroblastoma cell lines are shown in blue and red, respectively. Blue squares, 691-MES; blue circles, SH-EP2; red circles, SH-SY5Y; red squares, 691-ADRN; red diamonds, IMR-32; red triangles, MSC. (C) Thresholds for positivity in bone marrow (BM), peripheral blood (PB), and peripheral blood stem cell (PBSC) samples.
positive for MES mRNA if the Ct value was within the quantitative range,\textsuperscript{38} with no measurable expression of FMO3 (Fig 4C). We therefore tested whether these three molecular markers combined with these established thresholds can be used to detect neuroblastoma-derived MES mRNA in patient samples.

**Testing of the MES MRD Panel in Serial PB and PBSC Samples From Patients With High-Risk Neuroblastoma**

In 67 serial PB and 15 PBSC samples obtained from 12 patients with high-risk neuroblastoma, we measured PHOX2B and MES mRNA (Data Supplement). PHOX2B mRNA was detected in all diagnostic samples; this expression decreased to undetectable levels in most patients during induction chemotherapy (IC) and was detected again at relapse. In contrast, MES mRNA was detected in only six samples; five of these samples were PBSCs, and of note, these PBSC samples were negative for PHOX2B mRNA.

Next, we examined PBSC samples obtained from 53 patients with high-risk neuroblastoma who were previously studied using ADRN mRNA\textsuperscript{39} (Data Supplement). MES mRNA and ADRN mRNA were detected in 15 (28%) and six (11%) of 53 samples, respectively, with little overlap (both MES and ADRN mRNA were detected in only one sample). We previously reported that ADRN mRNA positivity is not correlated with outcome.\textsuperscript{39} However, here we found that the presence of POSTN and/or PRRX1 mRNA in PBSC samples was significantly associated with low event-free survival ($P = .045$) and low overall survival ($P = .047$; Fig 5; Data Supplement). Moreover, consistent with our previous findings, we found no correlation between ADRN mRNA and outcome (Data Supplement).

**Testing of the MES MRD Panel in BM From Patients With High-Risk Neuroblastoma**

We then examined the feasibility of using these RT-qPCR–based markers to study response kinetics in BM samples obtained from patients with high-risk neuroblastoma who experienced recurrent disease ($n = 16$) and from those with high-risk neuroblastoma who remained in complete remission ($n = 13$). Specifically, we compared PHOX2B mRNA with MES mRNA measured in 95 serial BM samples collected at diagnosis, during therapy, during follow-up, and (where applicable) during relapse (Fig 6; Data Supplement). PHOX2B mRNA was detected in all 27 diagnostic BM samples; this expression decreased during IC treatment and was undetectable by the end of IC in most patients (nine of 10 patients with complete remission and 10 of 15 patients who experienced relapse). In the patients with recurrent disease, PHOX2B mRNA was detected again in 75% (nine of 12 patients) with systemic relapse (three of the 15 patients with recurrent disease had a local relapse). In contrast, MES mRNA was detected in only 14 of 27 patients at diagnosis, and this number increased to 18 during IC treatment. In analyzing the entire patient group, we found that the prevalence of MES mRNA was significantly higher in the patients who experienced relapse (29 of 54 samples; 53%) compared with the patients with complete remission (13 of 41 samples; 32%; $P = .03$). Finally, we identified two BM samples and one PBSC sample that were negative for all ADRN mRNA markers but were positive for MES mRNA. Moreover, we detected hypermethylated RASSF1A DNA, a marker for neuroblastoma,\textsuperscript{34} in these samples (Fig 6D). We conclude that the kinetics differ between MES mRNA and ADRN mRNA, and MES positivity is significantly higher in the BM of patients with high-risk neuroblastoma.
Finally, using the tumor-specific DNA marker hypermethylated RASSF1A, we found that BM samples that are both ADRN negative and MES positive contain neuroblastoma cells.

**DISCUSSION**

RT-qPCR–based testing of BM of patients with neuroblastoma is a robust, highly sensitive, and clinically important method for detecting residual disease. However, even high-risk patients who have low or undetectable posttherapy mRNA levels can experience a relapse (48% to 60%).

Cellular heterogeneity is a key feature of many cancer types and is caused in part by EMT. We found that the commonly used neuroblastoma MRD markers are expressed predominantly in ADRN cell lines but are rarely expressed in MES cell lines. Thus, neuroblastoma cells that undergo EMT may not be detected using the current MRD marker panel. Ideally, an effective MRD marker should detect the full spectrum of neuroblastoma cell types, including ADRN and MES cells. We found that GD2S is expressed at high levels in both MES and ADRN cell lines; however, its specificity is limited because of its relatively high expression in normal hematologic cells.

To study the expression of MES-specific markers at the time of diagnosis as well as the dynamic expression pattern during follow-up, we identified a panel of markers that includes POSTN and PRRX1, which have been linked to EMT in several cancer types. An MRD marker ideally should be expressed at extremely low levels in normal hematologic cells. In our search for MES MRD markers, we performed gene expression analysis. However, a possible limitation of this approach is that dependent on the platform used, the actual gene expression levels can be underestimated, for example, as in the case of PRRX1 expression in one cell line used in our study. Moreover, genes that have not been reported to be expressed in PB data sets may indeed be expressed on the basis of RT-qPCR analysis. For example, RT-qPCR analysis revealed that both POSTN and PRRX1 are expressed at relatively weak levels in control BM samples, whereas these genes are expressed at barely detectable levels in control PB samples and control PBSCs. A subset analysis revealed that the expression was primarily the result of expression in MSCs; therefore, we added the
discriminative marker FMO3 to our panel, as this gene is expressed by MSCs but not by neuroblastoma cells. Of note, although we ascribed the expression of POSTN and PRRX1 in control BM samples to MSCs, we cannot rule out the possibility that other cell types, such as osteoblasts, may also contribute to this expression. Nevertheless, because we established strict thresholds for defining positivity, we believe that we avoided detection of normal stromal cells as well as other cell types.

Because MES mRNA was rarely detected in PB samples obtained from patients with high-risk neuroblastoma, its clinical relevance remains unclear, and these results need to be confirmed using a larger cohort. In contrast, MES mRNA was detected in 28% of the PBSC samples obtained from 53 patients and was significantly associated with low event-free survival and overall survival. Of note, we previously reported a relatively low prevalence (9%) of ADRN mRNA in PBSCs obtained from this cohort, and the presence of ADRN mRNA was not associated with either low event-free survival or low overall survival. Therefore, we speculate that the MES cells that reside in the BM circulate during stem-cell mobilization.

By focusing on serial BM samples in high-risk patients, we found that MES mRNA and ADRN mRNA have distinct temporal dynamics. Specifically, ADRN mRNA levels were high at diagnosis and during relapse but decreased during treatment, whereas MES mRNA levels increased during treatment and were associated with patients who ultimately had a relapse. This finding suggests that MES cells may respond differently to therapy compared with ADRN neuroblastoma cells and may play an important role in disease progression and/or recurrence; this notion is consistent with reports that demonstrated the importance of EMT in disease progression and treatment resistance. Moreover, our finding that MES mRNA was detected in only 14 of 27 patients at diagnosis (and only rarely at relapse) is consistent with the hypothesis that metastatic cells can undergo an MES-to-epithelial conversion and thus revert to an ADRN phenotype. The relatively small size of our patient cohorts precluded extensive multivariable analyses of survival; however, these exploratory findings suggest that detection of MES markers in the BM and PBSCs during treatment may have prognostic value.

DNA markers for MRD (and recently, circulating cell-free DNA markers) have been shown to provide added value when combined with RNA-based methods for monitoring MRD and for measuring tumor-derived genetic aberrations. On the other hand, we previously reported discrepancies between RNA-based and DNA-based markers using either methylated RASSF1A or patient-specific DNA markers. We hypothesize that these discrepancies reflect MES neuroblastoma cells that express reduced levels of ADRN markers but can still be detected using DNA markers.

In conclusion, we report that POSTN, PRRX1, and FMO3 mRNA can be used to detect MES neuroblastoma cells in BM and PBSCs in patients with high-risk neuroblastoma. Of note, we also found that MES-based markers have a different expression pattern during treatment than ADRN-based markers. Moreover, although the MES markers are more prevalent in the BM of patients who will ultimately experience relapse, they are rarely present at the actual time of relapse. To study the clinical implications and significance of these finding, this new panel of MES markers should be tested together with currently used MRD markers in a large prospective study.
REFERENCES

1. Laprie A, Michon J, Hartmann O, et al: High-dose chemotherapy followed by locoregional irradiation improves the outcome of patients with international neuroblastoma staging system stage II and III neuroblastoma with MYCN amplification. Cancer 101:1081-1089, 2004
2. Maris JM: Recent advances in neuroblastoma. N Engl J Med 362:2202-2211, 2010
3. Maris JM, Hogarty MD, Bagatell R, et al: Neuroblastoma. Lancet 369:2106-2120, 2007
4. Matthay KK: Intensification of therapy using hematopoietic stem-cell support for high-risk neuroblastoma. Pediatr Transplant 3:72-77, 1999
5. Brodeur GM, Maris JM, Yamashiro DJ, et al: Biology and genetics of human neuroblastomas. J Pediatr Hematol Oncol 19:93-101, 1997
6. Matthay KK, Villablanca JG, Seeger RC, et al: Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. N Engl J Med 341:1165-1173, 1999
7. Yu AL, Gilman AL, Ozkaynak MF, et al: Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 363:1324-1334, 2010
8. Seeger RC, Reynolds CP, Gallego R, et al: Quantitative tumor cell content of bone marrow and blood as a predictor of outcome in stage IV neuroblastoma: A Children's Cancer Group Study. J Clin Oncol 18:4067-4076, 2000
9. Beiske K, Burchill SA, Cheung IY, et al: Consensus criteria for sensitive detection of minimal neuroblastoma cells in bone marrow, blood and stem cell preparations by immunocytochemistry and QRT-PCR: Recommendations by the International Neuroblastoma Risk Group Task Force. Br J Cancer 100:1627-1637, 2009
10. Stutterheim J, Gemtzen A, Zappeij-Kannegieter L, et al: Detecting minimal residual disease in neuroblastoma: The superiority of a panel of real-time quantitative PCR markers. Clin Chem 55:1316-1326, 2009
11. Stutterheim J, Zappeij-Kannegieter L, Versteeg R, et al: The prognostic value of fast molecular response of marrow disease in patients aged over 1 year with stage 4 neuroblastoma. Eur J Cancer 47:1193-1202, 2011
12. Burchill SA, Lewis IJ, Abrams KR, et al: Circulating neuroblastoma cells detected by reverse transcriptase polymerase chain reaction for tyrosine hydroxylase mRNA are an independent poor prognostic indicator in stage 4 neuroblastoma in children over 1 year. J Clin Oncol 19:1795-1801, 2001
13. Cheung IY, Lo Piccolo MS, Kushner BH, et al: Early molecular response of marrow disease to biologic therapy is highly prognostic in neuroblastoma. J Clin Oncol 21:3863-3868, 2003
14. Marachelian A, Villablanca JG, Liu CW, et al: Expression of five neuroblastoma genes in bone marrow or blood of patients with relapsed/refractory neuroblastoma provides a new biomarker for disease and prognosis. Clin Cancer Res 23:5374-5383, 2017
15. Cheung IY, Feng Y, Gerald W, et al: Exploiting gene expression profiling to identify novel minimal residual disease markers of neuroblastoma. Clin Cancer Res 14:7020-7027, 2008
16. Hartomo TB, Kozaki A, Hasegawa D, et al: Minimal residual disease monitoring in neuroblastoma patients based on the expression of a set of real-time RT-PCR markers in tumor-initiating cells. Oncol Rep 29:1629-1636, 2013
17. Hirase S, Saitoh A, Hartomo TB, et al: Early detection of tumor relapse/regrowth by consecutive minimal residual disease monitoring in high-risk neuroblastoma patients. Oncol Lett 12:1119-1223, 2016
18. Viprey VF, Gregory WM, Corrias MV, et al: Neuroblastoma mRNAs predict outcome in children with stage 4 neuroblastoma: A European HR-NBL1/SIOPEN study. J Clin Oncol 32:1074-1083, 2014
19. Burchill SA, Beiske K, Shimada H, et al: Recommendations for the standardization of bone marrow disease assessment and reporting in children with neuroblastoma on behalf of the International Neuroblastoma Response Criteria Bone Marrow Working Group. Cancer 123:1095-1105, 2017
20. Dave B, Mintal V, Tan NM, et al: Epithelial-mesenchymal transition, cancer stem cells and treatment resistance. Breast Cancer Res 14:202, 2012
21. Chaffer CL, Weinberg RA: A perspective on cancer cell metastasis. Science 331:1569-1564, 2011
22. Yu M, Bardia A, Wittner BS, et al: Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science 339:580-584, 2013
23. van Groningen T, Koster J, Valentinj LJ, et al: A NOTCH feed-forward loop drives reprogramming from adrenergic to mesenchymal state in neuroblastoma. Nat Commun 10:1530, 2019
24. van Groningen T, Koster J, Valentinj LJ, et al: Neuroblastoma is composed of two super-enhancer-associated differentiation states. Nat Genet 49:1261-1266, 2017
25. Boeva V, Louis-Brennetot C, Peltier A, et al: Heterogeneity of neuroblastoma cell identity defined by transcriptional circuitries. Nat Genet 49:1408-1413, 2017
26. Debruyne DN, Bhatnagar N, Sharma B, et al: ALK inhibitor resistance in ALK(F1174L)-driven neuroblastoma is associated with AXL activation and induction of EMT. Oncogene 35:3681-3691, 2016
27. Piskareva O, Harvey H, Nolan J, et al: The development of cisplatin resistance in neuroblastoma is accompanied by epithelial to mesenchymal transition in vitro. Cancer Lett 364:142-155, 2015 [Erratum: Cancer Lett 369:428, 2015]
28. Stutterheim J, Gemtzen A, Zappeij-Kannegeiter L, et al: PHOX2B is a novel and specific marker for minimal residual disease testing in neuroblastoma. J Clin Oncol 26:5443-5449, 2008
29. Burchill SA, Bradbury FM, Smith B, et al: Neuroblastoma cell detection by reverse transcriptase-polymerase chain reaction (RT-PCR) for tyrosine hydroxylase mRNA. Int J Cancer 57:671-675, 1994

AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/po/author-center.

Disclosures of potential conflicts of interest were reported.

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).
30. Bate-Eya LT, Ebus ME, Koster J, et al: Newly-derived neuroblastoma cell lines propagated in serum-free media recapitulate the genotype and phenotype of primary neuroblastoma tumours. Eur J Cancer 50:628-637, 2014
31. van Nes J, Chan A, van Groningen T, et al: A NOTCH3 transcriptional module induces cell motility in neuroblastoma. Clin Cancer Res 19:3485-3494, 2013
32. Simon T, Berthold F, Borkhardt A, et al: Treatment and outcomes of patients with relapsed, high-risk neuroblastoma: Results of German trials. Pediatr Blood Cancer 56:578-583, 2011
33. Kraal KC, Bleeker GM, van Eck-Smit BL, et al: Feasibility, toxicity and response of upfront metaiodobenzylguanidine therapy followed by German Pediatric Oncology Group Neuroblastoma 2004 protocol in newly diagnosed stage 4 neuroblastoma patients. Eur J Cancer 76:188-196, 2017
34. Stutterheim J, Ichou FA, den Ouden E, et al: Methylated RASSF1a is the first specific DNA marker for minimal residual disease testing in neuroblastoma. Clin Cancer Res 18:808-814, 2012
35. Maijenburg MW, Noort WA, Kleijer M, et al: Cell cycle and tissue of origin contribute to the migratory behaviour of human fetal and adult mesenchymal stromal cells. Br J Haematol 148:428-440, 2010
36. Cheung IY, Lo Piccolo MS, Kushner BH, et al: Quantitation of GD2 synthase mRNA by real-time reverse transcriptase polymerase chain reaction: Clinical utility in evaluating adjuvant therapy in neuroblastoma. J Clin Oncol 21:1087-1093, 2003
37. Viprey VF, Lastowska MA, Corrias MV, et al: Minimal disease monitoring by QRT-PCR: Guidelines for identification and systematic validation of molecular markers prior to evaluation in prospective clinical trials. J Pathol 216:245-252, 2008
38. Gabert J, Beillard E, van der Velden VH, et al: Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia—A Europe Against Cancer program. Leukemia 17:2318-2357, 2003
39. van Wezel EM, Stutterheim J, Vree F, et al: Minimal residual disease detection in autologous stem cell grafts from patients with high risk neuroblastoma. Pediatr Blood Cancer 62:1368-1373, 2015
40. Morra L, Moch H: Periostin expression and epithelial-mesenchymal transition in cancer: A review and an update. Virchows Arch 459:465-475, 2011
41. Wu SQ, Lu Piccolo MS, Kushner BH, et al: Silencing of periostin inhibits nicotine-mediated tumor cell growth and epithelial-mesenchymal transition in lung cancer cells. Mol Med Rep 7:875-880, 2013
42. Guo J, Fu Z, Wei J, et al: PRRX1 promotes epithelial-mesenchymal transition through the Wnt/b-catenin pathway in gastric cancer. Med Oncol 32:393, 2015
43. Takahashi Y, Sawada G, Kurashige J, et al: Paired related homeobox 1, a new EMT inducer, is involved in metastasis and poor prognosis in colorectal cancer. Br J Cancer 109:307-311, 2013
44. Nakazawa Y, Taniyama Y, Sanada F, et al: Periostin blockade overcomes chemoresistance via restricting the expansion of mesenchymal tumor subpopulations in breast cancer. Sci Rep 8:4013, 2018
45. Fischer KR, Durrans A, Lee S, et al: Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Nature 527:472-476, 2015
46. Kalluri R, Weinberg RA: The basics of epithelial-mesenchymal transition. J Clin Invest 119:1420-1428, 2009
47. van Wezel EM, Zwijnenburg D, Zappeij-Kannegieter L, et al: Whole-genome sequencing identifies patient-specific DNA minimal residual disease markers in neuroblastoma. J Mol Diagn 17:43-52, 2015
48. Kryh H, Abrahamsson J, Jegerás E, et al: MYCN amplicon junctions as tumor-specific targets for minimal residual disease detection in neuroblastoma. Int J Oncol 39:1063-1071, 2011
49. Chicard M, Colmet-Daage L, Clement N, et al: Whole-exome sequencing of cell-free DNA reveals temporo-spatial heterogeneity and identifies treatment-resistant clones in neuroblastoma. Clin Cancer Res 24:939-949, 2018
APPENDIX

Microarray Analysis

Mesenchymal (MES)-specific candidate markers were identified by comparing gene expression profiles (Human Genome U133 Plus 2.0 Array; Affymetrix, Santa Clara, CA) among the following isogenic pairs of adrenergic (ADRN) and MES cell lines: 691-MES/691B-ADRN, SH-EP2 (MES)/SH-SY5Y (ADRN), 700-MES/700-ADRN. Specifically, we screened for genes with a 1 log-fold or more difference in expression (within each isogenic pair) and an expression level greater than 400 units, thereby selecting only highly expressed marker genes. To identify discriminating markers for normal mesenchymal stromal cells (MSCs), the top 300 genes with the highest expression were used (Gene Expression Omnibus: GSE68374); the genes with the highest fold difference between MSCs and MES neuroblastoma cell lines were then selected. For each analysis, each gene’s expression was compared with its corresponding expression level in reference blood samples obtained from five different data sets (GSE13159, GSE17186, GSE10715, GSE8121, and GSE6575); only genes that are not expressed in hematologic cell types (using HaemAtlas; Watkins et al: Blood 113:e1-e9, 2009) were selected. All gene expression analyses were performed in the genomics analysis and visualization platform R2 (http://r2.amc.nl).

RNA Extraction and Real-Time Quantitative Polymerase Chain Reaction

cDNA was synthesized using 2 to 3 μg RNA, random hexamers (25 μM; Invitrogen, Carlsbad, CA), deoxynucleotide triphosphates (1 mM; Promega, Madison, WI), and Moloney murine leukemia virus reverse transcriptase (100 U; Invitrogen) in a total reaction volume of 40 to 60 μL. The reverse transcription was then heat inactivated, and the reaction volume was increased to 100 to 150 μL.

Primers and probes were designed using Primer Express version 1.5 software (Applied Biosystems, Foster City, CA) or Oligo 6 (Molecular Biology Insights, Colorado Springs, CO) and synthesized by Eurogentec (Liege, Belgium; Data Supplement). The primer/probe combinations for glucuronidase-β (GUSB), β-1,4-N-acetyl-galactosaminyltransferase 1 (B4GALNT1, also known as GD2S), paired-like homeobox 2B (PHOX2B), tyrosine hydroxylase (TH), dopa decarboxylase (DDC), growth-associated protein 43 (GAP43), cholinergic receptor nicotinic α3 (CHRNA3), and dopamine β-hydroxylase (DBH) have been published previously10,36,37 (Beillard et al: Leukemia 17:2474-2486, 2003). Real-time quantitative polymerase chain reaction (RT-qPCR; maximum, 50 cycles) was performed using Step-OnePlus (Applied Biosystems). The initial screening for candidate molecular markers was performed using SYBR Green I dye (Applied Biosystems) combined with a melting curve analysis followed by specific TaqMan probes (Eurogentec). Expression was normalized to GUSB expression using the following equation: normalized threshold cycle (dCt) = (CtGUSB − Ctmarker). All RT-qPCR reactions were performed in triplicate (except GUSB, which was performed in duplicate), and mean values were used for analysis. A given sample was scored as follows: positive if all three replicates were positive; positive not quantifiable if amplification was observed in only one or two replicates; and negative if the Ct value was 40 or greater (with the exception of PHOX2B [Ct ≥ 50]).10,28 Samples with an insufficient CtGUSB value (Ct > 25, corresponding to ≤ 500 copies) were excluded28,38 (Beillard et al: Leukemia 17:2474-2486, 2003). The sensitivity and quantitative range of each RT-qPCR assay were assessed using cDNA prepared from 691-MES cells and serially diluted in water.